ASCO “Top 5” List Turns Up Rhetorical Heat On Cancer Drug Prices
This article was originally published in RPM Report
Executive Summary
“Financial toxicity” should be considered by oncologists in use of new, targeted therapies, oncology association says. A new list of practices to avoid puts drug costs more squarely in crosshairs than first version in 2012.